A Trial Comparing Circumferential Casting Versus Splinting in Displaced Colles' Fractures
Launched by UNIVERSITY OF BRITISH COLUMBIA · Jun 24, 2008
Trial Information
Current as of August 24, 2025
Completed
Keywords
ClinConnect Summary
Primary: To determine the effectiveness of three immobilization methods (circumferential cast \[CC\], volar dorsal splint \[VDS\], modified sugar-tong \[MST\] splint) in maintaining the position of displaced distal radius fractures after successful closed reduction.
Secondary to assess long term functional outcomes associated with fiberglass splint immobilization versus standard cylindrical casting in patients maintaining initial non-operative reductions.
Design: Randomized prospective single blind controlled trial Patients/Participants: Patients over 18 years of age who presented to the ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \> 18 years
- • Displaced fracture of distal radius requiring closed reduction
- Exclusion Criteria:
- • Open fracture
- • Previous displaced fracture involving the same or contralateral distal radius
- • neuromuscular deficits or CVA of either upper extremity that impaired functional outcome assessment
- • concurrent carpal bone fractures or dislocations - - unstable fractures requiring primary open reduction and internal fixation
- • skin allergy or sensitivity to either of the immobilization materials
- • Smith's, Barton's or Chauffeur fractures
- • Neurovascular compromise of the affected limb - - Bilateral distal radius fractures that prevented follow-up comparison with a normal contralateral limb
- • Other significant and concurrent injuries in the ipsilateral extremity.
- • Undisplaced distal radius fracture
- • Reduction performed in the ED did not meet criteria for successful fracture reduction
About University Of British Columbia
The University of British Columbia (UBC) is a leading research institution located in Vancouver, Canada, renowned for its commitment to advancing health sciences through innovative research and education. As a prominent clinical trial sponsor, UBC leverages its interdisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies aimed at improving patient outcomes across various medical fields. The university fosters collaborations with healthcare professionals, industry partners, and community stakeholders to translate research findings into practical applications, thereby contributing to the global advancement of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vancouver, British Columbia, Canada
Patients applied
Trial Officials
Robert Stenstrom, MD, Ph.D
Principal Investigator
University of British Columbia
Eric Grafstein, MD
Study Director
University of British Columbia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials